

**Disclosure Team**

The Association of the British Pharmaceutical Industry
7th Floor, Southside
105 Victoria Street
London
SW1E 6QT

Date: 27/03/2018**Disclosure of transfers of value to healthcare professionals and healthcare organisations**

Dear Disclosure Team,

Syner-Med (PP) Ltd. is currently not member of ABPI, however, voluntarily agreed to abide by ABPI Code of Practice in all aspects of commercial and non-commercial activities, particularly interactions with healthcare professionals (HCPs) and healthcare organisations (HCOs). Syner-Med follows the ABPI Code of Practice with regards to any payments (Sponsorships, Registration fee, honoraria etc.) made to HCPs and HCOs in accordance to Clause 1.4, 1.9, 20, 21, 22, 23 & 24.

METHODOLOGY

Syner-Med has Policies and Standard Operating Procedures (SOP) in place in line with ABPI Code of Practice, e.g. Sponsorship/Grant Requests, Advisory Boarding, Meetings and Hospitality and all such requests are processed and approved as per relevant policies and SOPs. Honoraria for consultancy work or Advisory Board meetings etc. are calculated on Fair Market Value (FMV) based on HCPs' role, seniority, time (excluding travel times), hourly/daily rates and industry average.

Syner-Med maintains complete record of all sponsorship/grant requests and payment made to HCPs and HCOs. In the disclosure template multiple payments made have been aggregated into one entry for each HCP or HCO. Amount paid are then subdivided into appropriate categories, i.e. sponsorship, registration, honorarium, travel and accommodation expenses.

In column AC – rows 5-6 of the disclosure template, amounts paid to each HCP during 2017 have been summed. Total of the payments made to all HCPs in 2017 by Syner-Med (PP) Ltd is £22,024.26. Syner-Med did not make any payments to HCOs in 2017 for either joint working, donations, grants, sponsorships, benefits in kind or any other.

However, Syner-Med has made payments to HCPs and HCOs for non-interventional studies; single centre prospective observational study (£1,500), a national prospective audit (£24.00) (payments to continue into 2018), and finally a clinical trial (£7,304.85). All of which have been documented in Research and Development as per Clause 23.2 in column Z – row 50. The total amount of which is £8,828.85.

Should you require any further information in this matter, please do not hesitate to contact me.

Yours faithfully,

A handwritten signature in black ink, appearing to read 'Khalil Ahmed', with a horizontal line underneath.

Khalil Ahmed

Head of Medical Affairs

Direct Line: 02086556388

Email: khalila@syner-med.com